Literature DB >> 20414098

PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.

Anna R Laury1, Jason L Hornick, Ruth Perets, Jeffrey F Krane, Joseph Corson, Ronny Drapkin, Michelle S Hirsch.   

Abstract

Ovarian serous neoplasms can have morphologic overlap with malignant mesothelioma. The distinction is clinically important, yet most studies have failed to identify immunostains that reliably distinguish these 2 tumor types. Recently, transcription factor PAX8 was shown to be a sensitive and relatively specific marker for Müllerian tumors. In addition, some studies suggest that h-caldesmon is sensitive and specific for mesothelioma when compared with serous ovarian tumors. The goal of this study was to evaluate whether PAX8 and h-caldesmon expression can successfully distinguish mesothelioma from serous ovarian tumors. Immunohistochemistry was carried out using PAX8 and h-caldesmon antibodies on archival tissue from 254 ovarian serous tumors and 50 mesothelial tumors. Nuclear and cytoplasmic immunoreactivity were considered positive for PAX8 and h-caldesmon, respectively. PAX8 staining was present in 99% of high-grade serous ovarian carcinomas and all (100%) low-grade ovarian carcinomas and serous borderline tumors; however, only 74% of these cases (188/254) were diffusely positive in more than 50% of tumors cells, and intensity ranged from strong to weak. None of the pleural malignant mesotheliomas were reactive with PAX8. However, 2/23 (9%) peritoneal malignant mesotheliomas showed focal and/or weak staining for PAX8; the remaining cases were negative. Two well-differentiated papillary mesotheliomas and 1 multicystic mesothelioma each showed some staining for PAX8. h-caldesmon was negative in all serous neoplasms and all mesothelial neoplasms, except 1 pleural malignant mesothelioma which showed patchy immunoreactivity. Strong PAX8 staining is highly specific (P<0.00001) for ovarian serous tumors when compared with malignant mesotheliomas of the peritoneum and pleura. The presence of weak staining for PAX8 in the 3 "noninvasive" mesotheliomas questions the use for PAX8 in this differential diagnosis. On the basis of this study, h-caldesmon is not a useful marker for mesothelioma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20414098     DOI: 10.1097/PAS.0b013e3181da7687

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  64 in total

1.  Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer.

Authors:  Ludmila Szabova; Chaoying Yin; Sujata Bupp; Theresa M Guerin; Jerome J Schlomer; Deborah B Householder; Maureen L Baran; Ming Yi; Yurong Song; Wenping Sun; Jonathan E McDunn; Philip L Martin; Terry Van Dyke; Simone Difilippantonio
Journal:  Cancer Res       Date:  2012-05-22       Impact factor: 12.701

2.  Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models.

Authors:  Ruth Perets; Gregory A Wyant; Katherine W Muto; Jonathan G Bijron; Barish B Poole; Kenneth T Chin; Jin Yun H Chen; Anders W Ohman; Corey D Stepule; Soongu Kwak; Alison M Karst; Michelle S Hirsch; Sunita R Setlur; Christopher P Crum; Daniela M Dinulescu; Ronny Drapkin
Journal:  Cancer Cell       Date:  2013-12-09       Impact factor: 31.743

3.  Adenomatoid tumors of the female and male genital tract. A comparative clinicopathologic and immunohistochemical analysis of 47 cases emphasizing their site-specific morphologic diversity.

Authors:  David L Wachter; Peter H Wünsch; Arndt Hartmann; Abbas Agaimy
Journal:  Virchows Arch       Date:  2011-02-20       Impact factor: 4.064

4.  Primary culture and immortalization of human fallopian tube secretory epithelial cells.

Authors:  Alison M Karst; Ronny Drapkin
Journal:  Nat Protoc       Date:  2012-08-30       Impact factor: 13.491

5.  The diagnostic role of PTEN and ARID1A in serous effusions.

Authors:  Ben Davidson; Maurizio Pinamonti; Dolors Cuevas; Arild Holth; Pio Zeppa; Thomas Hager; Jeremias Wohlschlaeger; Martin Tötsch
Journal:  Virchows Arch       Date:  2017-11-24       Impact factor: 4.064

6.  Malignant pericardial mesothelioma : A systematic review of current practice.

Authors:  S Cao; S Jin; J Cao; J Shen; H Zhang; Q Meng; B Pan; Y Yu
Journal:  Herz       Date:  2017-01-27       Impact factor: 1.443

7.  Ascites analysis by a microfluidic chip allows tumor-cell profiling.

Authors:  Vanessa M Peterson; Cesar M Castro; Jaehoon Chung; Nathan C Miller; Adeeti V Ullal; Maria D Castano; Richard T Penson; Hakho Lee; Michael J Birrer; Ralph Weissleder
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

8.  PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma.

Authors:  Dima Ghannam-Shahbari; Eyal Jacob; Reli Rachel Kakun; Tanya Wasserman; Lina Korsensky; Ofir Sternfeld; Juliana Kagan; Debora Rosa Bublik; Sarit Aviel-Ronen; Keren Levanon; Edmond Sabo; Sarit Larisch; Moshe Oren; Dov Hershkovitz; Ruth Perets
Journal:  Oncogene       Date:  2018-01-30       Impact factor: 9.867

9.  Fallopian tube secretory cell expansion: a sensitive biomarker for ovarian serous carcinogenesis.

Authors:  Yiying Wang; Li Li; Yue Wang; Sarah Ngocvi Tang; Wenxin Zheng
Journal:  Am J Transl Res       Date:  2016-01-15       Impact factor: 4.060

10.  Epigenetic remodeling regulates transcriptional changes between ovarian cancer and benign precursors.

Authors:  Kevin M Elias; Megan M Emori; Thomas Westerling; Henry Long; Anna Budina-Kolomets; Fugen Li; Emily MacDuffie; Michelle R Davis; Alexander Holman; Brian Lawney; Matthew L Freedman; John Quackenbush; Myles Brown; Ronny Drapkin
Journal:  JCI Insight       Date:  2016-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.